These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12297389)

  • 1. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K).
    Watanabe I; Hagiwara Y; Kadowaki SE; Yoshikawa T; Komase K; Aizawa C; Kiyono H; Takeda Y; McGhee JR; Chiba J; Sata T; Kurata T; Tamura S
    Vaccine; 2002 Oct; 20(29-30):3443-55. PubMed ID: 12297389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.
    Asanuma H; Hirokawa K; Uchiyama M; Suzuki Y; Aizawa C; Kurata T; Sata T; Tamura S
    Vaccine; 2001 Jul; 19(28-29):3981-9. PubMed ID: 11427274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
    Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
    J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.
    Tamura S; Samegai Y; Kurata H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1988 Oct; 6(5):409-13. PubMed ID: 2848377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
    Asanuma H; Fujihashi K; Miyakoshi T; Yoshikawa T; Fujita-Yamaguchi Y; Kojima N; Nakata M; Suzuki Y; Tamura S; Kurata T; Sata T
    Vaccine; 2007 Sep; 25(39-40):6975-80. PubMed ID: 17716790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.
    Kadowaki S; Chen Z; Asanuma H; Aizawa C; Kurata T; Tamura S
    Vaccine; 2000 Jun; 18(25):2779-88. PubMed ID: 10812219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.
    Hagiwara Y; Komase K; Chen Z; Matsuo K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 1999 Jul; 17(22):2918-26. PubMed ID: 10438064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.
    Yoshikawa T; Suzuki Y; Nomoto A; Sata T; Kurata T; Tamura Si
    Vaccine; 2002 Nov; 21(1-2):60-6. PubMed ID: 12443663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit.
    Tamura S; Kurata H; Funato H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1989 Aug; 7(4):314-20. PubMed ID: 2815967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
    Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.
    Okamoto S; Matsuoka S; Takenaka N; Haredy AM; Tanimoto T; Gomi Y; Ishikawa T; Akagi T; Akashi M; Okuno Y; Mori Y; Yamanishi K
    Clin Vaccine Immunol; 2012 Jul; 19(7):979-90. PubMed ID: 22552600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
    Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.